Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to DNA expression vector or a mixture of DNA expression vectors which encodes at least two CD4 epitopes of telomerase reverse transcriptase (TERT) and at least one tumor, viral, bacterial, or parasitic CD8 epitope.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the ?3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Abstract: The present invention relates to methods for transferring a nucleic acid in vivo into skin cells wherein the nucleic acid is injected by intradermal (ID) injection and is electrically transferred into skin cells with a single pulse of a High Voltage, followed, after a defined lag time, by a single pulse of Low Voltage.

Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the a3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies. A particular embodiment refers to the monoclonal antibody with the arbitrary designation 15E7 for which the sequence is provided. Also a anti-HLA-G single-chain antibody gene library was generated and six specific binders were identified from that library.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: The present invention relates to DNA expression vector or a mixture of DNA expression vectors which encodes at least two CD4 epitopes of telomerase reverse transcriptase (TERT) and at least one tumor, viral, bacterial, or parasitic CD8 epitope.

Abstract: The present invention relates to methods for transferring a nucleic acid in vivo into skin cells wherein the nucleic acid is injected by intradermal (ID) injection and is electrically transferred into skin cells with a single pulse of a High Voltage, followed, after a defined lag time, by a single pulse of Low Voltage.

Abstract: The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Abstract: A new strain of Human Immunodeficiency Virus (HIV), which is the major etiological agent of Acquired Immune Deficiency Syndrome (AIDS), is identified. The new strain, products derived from the new strain, a diagnostic method for detecting antibodies to the strain in biological fluids, and a diagnostic kit for carrying out the method are described.